Lytix Biopharma (LYTIX) Q2 2025 earnings summary

Executive summary

• Advancing toward commercialization with a robust clinical pipeline, including LTX-315 (Ruxotemitide) moving toward Phase III in BCC and ongoing Phase II in melanoma, supported by a partnership with Verrica Pharmaceuticals.

• Strong clinical proof of concept in Phase II for LTX-315, with over 50% complete clearance in BCC and disease control in 40% of late-stage melanoma patients.

• Pipeline includes LTX-315 (late-stage and early-stage melanoma, BCC) and next-gen LTX-401 for deep-seated cancers, with preclinical progress.

• Board and management strengthened with commercial and regulatory expertise for late-stage development and business readiness.

• Significant reduction in net loss for Q2 2025, driven by a NOK 10.2 million accrual reversal related to the ATLAS-IT-05 study.

Financial highlights

• Q2 2025 net loss substantially reduced due to NOK 10.2 million reversal of prior accruals for ATLAS-IT-05 and lower R&D spend.

• Cash and short-term investments at NOK 100.3 million at end of June 2025, providing runway into 2026.

• Total liabilities decreased from NOK 38.6 million at year-end 2024 to NOK 20.1 million at June 2025.

• Total operating income for Q2 2025 was NOK 11.1 million; total operating expenses were NOK 21.5 million.

• Equity ratio improved to 81.7% as of June 30, 2025.

Outlook and guidance

• Interim NeoLIPA data to be presented at Nordic Melanoma Meeting in November 2025; top-line results expected first half 2026.

• Verrica to present additional phase II immune/genomic data and phase III plans for BCC at an international conference later in 2025.

• Next milestone payment from Verrica tied to start of phase III, likely first half 2026.

• LTX-401 clinical entry timing under review, dependent on LTX-315 progress.

• Continued focus on cost control and flexibility for key catalysts in H2 2025.